Adma Biologics Inc. (NASDAQ: ADMA) stock declined by 1.32% at the last close whereas the ADMA stock price gains by 11.40% in the pre-market trading session. ADMA Biologics is a full-service commercial pharmaceutical business focused on researching, producing, and selling specialized plasma-derived biologics for the therapy of immunocompromised patients and those at risk of infection.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s happening with ADMA stock?
ADMA Biologics confirmed today that its ADMA BioCenters plasma gathering facility in Maryville, Tennessee, has been approved by the US Food and Drug Administration. In the fourth quarter of 2020, this plasma collection plant began operations and began collecting source plasma. This facility is now FDA-licensed to gather and bring human source plasma into interstate commerce for further processing in the United States, pursuant to today’s approval.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Read More
This brand-new plasma collection center boasts computerized registration, high-tech collection equipment that speeds up the donation process, a free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable for each donor station, and extremely qualified and educated staff who prioritize donor comfort and safety. The plasma facility intends to have a team of 50 highly qualified healthcare personnel when it is fully operational. The Haemonetics NexSys Persona plasma collection system has been authorized for usage at this facility.
Adam Grossman, President and Chief Executive Officer of ADMA commented,
The licensing of this plasma collecting facility is a significant step forward in ADMA’s efforts to improve end-to-end management of manufacturing processes and secure raw material plasma supply. ADMA has eight plasma collection facilities under its group name, including three FDA-approved facilities, with five of them open and collecting plasma and two more Biologics License Applications submissions expected in the second half of 2021. By 2024, ADMA hopes to establish at least ten FDA-approved plasma collecting facilities. ADMA thinks it is protected from wider market plasma collection and pricing changes due to the continuation of third-party supply agreements until year-end 2022, as well as the projected yield increases coming from their recent adoption of Haemonetics’ NexSys Persona technology. The Company is at a valuable position to secure the supply of plasma goods and the continuation of their supply chain.
